SAN FRANCISCO – Elon Musk’s brain-implant startup Neuralink Corp. has leased a vacant building in South San Francisco, a fresh sign of the billionaire’s renewed interest in the Bay Area tech scene.
The lease adds to a refreshed and growing area presence for Musk, who moved several of his companies to Texas after criticizing California’s business climate during the pandemic.
Also Read:Tesla Cybertruck sales are stalling
Tesla Inc. and X Corp. relocated their headquarters to the Austin area as Musk shuttered Twitter Inc.’s San Francisco offices after renaming the social media platform X. He moved SpaceX headquarters to Starbase, his new company town in South Texas.
Also Read:Tesla Rolls Out Massive FSD Update That Mirrors Your Driving Style
Now, both Neuralink and Musk’s California-based artificial intelligence startup xAI are expanding in the Bay Area., with xAI reportedly scouting for even larger office space.
Neuralink’s new lease is for a 144,000-square-foot property that had been vacant since biotech firm InterVenn Biosciences pulled out of its lease in 2023, according to a report by the Business Times. Last year, Neuralink expanded its operations in Central Texas with construction of a 112,000-square-foot facility in suburban Austin.
Also Read:Opinion: Trump loves his tariffs. Too bad he’s wrong about them.
Founded in 2016, the Fremont, Calif., company has developed a brain-computer interface designed to help people with paralysis control devices with their thoughts. The company, valued at more than $3 billion, began human trials last year and says 12 patients worldwide now have its implant.
“The latency between a user’s intention and the system’s output is roughly 10 times faster than typical brain-to-muscle response,” president and co-founder DJ Seo told PC Mag in July.
Also Read:Kremlin warns the West over ‘dramatic’ escalation moment in Ukraine war
He added that Neuralink’s robotic surgical arm “could bring its implant to the masses,” noting a backlog of 10,000 people eager to participate.
The company has partnered with hospitals in the U.K. to expand its clinical research and recently raised $650 million in new funding.
Neuralink did not respond to a request for more information.